

## **Research Opportunity:** **Adults with MCAD Deficiency**

Dr. Jerry Vockley and his colleagues at the Children's Hospital of Pittsburgh of UPMC are conducting a 7-week evaluation of safety and biochemical changes of the drug Ravicti™ in MCAD patients. Ravicti™ is currently approved for treatment of urea cycle disorders, but laboratory studies in cells have suggested that Ravicti™ may also increase the amount of MCAD enzyme activity.

To be eligible for this study, you must be 18 years or older and have MCAD deficiency with at least one copy of the 985A>G mutation. Patients who have kidney or liver failure, or are pregnant or breastfeeding are not eligible. You must also be able to travel to Pittsburgh on four occasions and will be required to stay overnight in the Clinical Research Center for your first visit.

For more information, contact the research coordinator, Elizabeth McCracken, MS, CGC at (412)692-5662 or [Elizabeth.McCracken@chp.edu](mailto:Elizabeth.McCracken@chp.edu).

